In the Claims:

Please amend claims 1-7 and 9 as follows. Please add new claims 10-12.

1. (Currently Amended) A compound of formula (I):



(I)

wherein:

Y is phenyl, substituted with one, two or three substituents selected from C_{1-6} alkyl, halosubstitutedC_{1-6} alkyl, C_{1-6} alkoxy, hydroxy, cyano, halo, C_{1-6}alkylsulfonyl, COOH, halosubstitutedC_{1-6} alkoxy, $CONH_2$, $NHCOCH_3$, C_{1-6}alkynyl, C_{1-6}alkyenyl $SO_2NR^{8a}R^{8b}$ wherein R^{8a} and R^{8b} are independently selected from H and C_{1-6}alkyl;

R^1 is selected from hydrogen, C_{1-6} alkyl, C_{3-7} cycloalkyl, and ~~or~~ halosubstitutedC_{1-6} alkyl;

R^2 is $(CH_2)mR^3$;

R^3 is a an ~~unsubstituted or substituted~~ 5- to 6- membered aromatic heterocyclyl group unsubstituted or substituted with 1, 2 or 3 substitutents selected from C_{1-6} alkyl, C_{1-6} alkoxy, halosubstitutedC_{1-6} alkoxy, halosubstitutedC_{1-6} alkyl, hydroxy, cyano, halo, sulfonyl, $CONH_2$ and COOH, or group A:



(A)

R^4 is selected from hydrogen, C_{1-6} alkyl, C_{3-7} cycloalkyl, or halosubstitutedC_{1-6} alkyl, $COCH_3$, and SO_2Me;

R^6 is unsubstituted or substituted (C_{1-6})alkyl or chloro and R^{10} is hydrogen or R^{10} is unsubstituted or substituted (C_{1-6})alkyl or chloro and R^6 is hydrogen wherein said substituted (C_{1-6})alkyl is substituted with 1, 2 or 3

substitutents selected from hydroxy, C_{1-6}alkyoxy, cyano, halo, NR^{8a} R^{8b}, $CONR^{8a}R^{8b}$, $SO_2NR^{8a}R^{8b}$, $NR^{8a}COR^{8b}$ and NR^{8a} SO_2R^{8b};

Ra ~~can be~~ is independently selected from hydrogen, fluoro, chloro and ~~or~~ trifluoromethyl;

Rb ~~can~~ is independently ~~be~~ selected from hydrogen, C_{1-6} alkyl, C_{1-6} alkoxy, halo substituted C_{1-6} alkoxy, hydroxy, cyano, halo, sulfonyl, $CONH_2$, COOH, SO_2CH_3, $NHCOCH_3$, $NHSO_2CH_3$ and $CONHCH_3$;

m is 1 or 2;

or a pharmaceutically acceptable derivative thereof.

2. (Currently Amended) A compound ~~as claimed in claim 1 wherein the compound is~~ of formula (Ia):



(Ia)

wherein

R^1 is selected from hydrogen, C_{1-6} alkyl, C_{3-7} cycloalkyl, and ~~or~~ halosubstitutedC_{1-6} alkyl;

R^3 is furanyl, dioxalanyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, triazolyl, triazinyl, isothiazolyl, isoxazolyl, thienyl, pyrazolyl, tetrazolyl, pyridyl, pyrizinyl, pyrimidinyl, pyrazinyl, triazinyl, or tetrazinyl which can be unsubstituted or substituted with 1, 2 or 3 substitutents selected from C_{1-6} alkyl, C_{1-6} alkoxy, halosubstitutedC_{1-6} alkoxy, halosubstitutedC_{1-6} alkyl, hydroxy, cyano, halo, sulfonyl, $CONH_2$ and COOH, or R^3 is group A:



(A)

R^4 is selected from hydrogen, C_{1-6} alkyl, C_{3-7} cycloalkyl, or halosubstitutedC_{1-6} alkyl, $COCH_3$, and SO_2Me;

R^6 is unsubstituted or substituted (C_{1-6})alkyl, chloro and R^{10} is hydrogen or R^{10} is unsubstituted or substituted (C_{1-6})alkyl or chloro and R^6 is hydrogen wherein said substituted (C_{1-6})alkyl is substituted with 1, 2 or 3 substitutents selected from hydroxy, C_{1-6}alkyoxy, cyano, halo, $NR^{8a}R^{8b}$, $CONR^{8a}R^{8b}$, $SO_2NR^{8a}R^{8b}$, $NR^{8a}COR^{8b}$ and $NR^{8a}SO_2R^{8b}$;

Ra ~~can be~~ is independently selected from hydrogen, fluoro, chloro and ~~or~~ trifluoromethyl;

Rb ~~can~~ is independently ~~be~~ selected from hydrogen, C_{1-6} alkyl, C_{1-6} alkoxy, halosubstitutedC_{1-6} alkoxy, hydroxy, cyano, halo, sulfonyl, $CONH_2$, COOH, SO_2CH_3, $NHCOCH_3$, $NHSO_2CH_3$ and $CONHCH_3$;

R^{11} is C_{1-6} alkyl, halosubstitutedC_{1-6} alkyl, C_{1-6} alkoxy, hydroxy, cyano, halo, C_{1-6}alkylsulfonyl, $CONH_2$, $NHCOCH_3$, COOH, halosubstitutedC_{1-6} alkoxy, C_{1-6}alkynyl, C_{1-6}alkynyl, $SO_2NR^{8a}R^{8b}$;

d is 1, 2, or 3:

m is 1 or 2;

R^{8a} and R^{8b} are independently selected from hydrogen and ~~or~~ C_{1-6}alkyl;

or a pharmaceutically acceptable derivative thereof.

3. (Currently Amended) A compound as claimed in claim 1 ~~or 2~~ wherein R^1 is hydrogen or C_{1-6}alkyl

4. (Currently Amended) A compound as claimed in claim 1 ~~any one of claims 1 to 3~~ wherein R^4 is hydrogen or methyl.

5. (Currently Amended) A compound as claimed in claim 1 wherein ~~any preceeding claim whereing~~ R^3 is selected from group A, pyridinyl, pyrimidinyl, imidazoyl, oxadiazoyl, triazolyl and ~~or~~ pyrazinyl any of which are unsubstituted or substituted with 1, 2 or 3 substitutents selected from C_{1-6} alkyl, C_{1-6} alkoxy, halosubstitutedC_{1-6} alkoxy, hydroxy, cyano, halo, sulfonyl, $CONH_2$ and COOH.

6. (Currently Amended) A compound ~~as claimed in any preceeding claim~~ selected from any one of Examples 1 to 79 or a pharmaceutically acceptable derivative thereof.

7. (Currently Amended) A pharmaceutical composition comprising a compound as claimed in claim 1 ~~any one of claims 1 to 6 or a pharmaceutically acceptable derivative thereof~~.

8. (Original) A pharmaceutical composition as claimed in claim 7 further comprising a pharmaceutical carrier or diluent thereof.

9. (Currently Amended) A method of treating a ~~human or animal subject~~ mammal suffering from a condition which is mediated by the activity of cannabinoid 2 receptors which comprises administering to said mammal ~~subject~~ a therapeutically effective amount of a compound ~~of formula (I)~~ as claimed in claim 1 ~~any one of claims 1 to 6 or a pharmaceutically acceptable derivative thereof~~.

10. (New) The method as claimed in claim 9, wherein said condition is selected from an immune disorder, an inflammatory disorder, pain, rheumatoid arthritis, multiple sclerosis, osteoarthritis and osteoporosis

11. (New) The method as claimed in claim 10, wherein said pain is selected from inflammatory pain, viseral pain, cancer pain, neuropathic pain, lower back pain, muscular sceletal, post operative pain, acute pain and migraine.

12. (New) The method as claimed in claim 9, wherein said mammal is a human.